Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.
Drooling is a common and incapacitating problem in Parkinson's disease (PD). Treatment with botulinum neurotoxin (BoNT) into the parotid glands seems beneficial. Injection of the submandibular glands may also be effective since these produce 70% of the daily unstimulated saliva. We randomly allocated patients to BoNT injections into the submandibular glands or the parotid glands. Within-group improvements were significant for the submandibular group, but not for the parotid group. Between-group differences showed a trend towards superiority for the submandibular group. Injecting the submandibular glands instead of the parotid glands seems a promising approach, and larger studies are justified.
Kalf
Johanna G
JG
Department of Allied Health Occupations, Speech Language Therapy, Radboud University Nijmegen Medical Centre, The Netherlands.
Smit
Anne M
AM
Bloem
Bastiaan R
BR
Zwarts
Machiel J
MJ
Mulleners
Wim M
WM
Munneke
Marten
M
D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004333:Drug Administration Routes; D006801:Humans; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology; D010306:Parotid Gland / Q000187:drug effects*; D010865:Pilot Projects; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D013363:Submandibular Gland / Q000187:drug effects*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A